BACKGROUND AND PURPOSE: Widespread pain sensitivity in patients with fibromyalgia (FM) suggests a central nervous system (CNS)-processing problem. Therefore, it is conceivable that metabolic alterations exist in pain-processing brain regions of people with FM compared with healthy controls (HC) and that such metabolic data could correlate with clinical symptoms. The purpose of this study was to test these hypotheses using proton MR spectroscopy ((1)H-MR spectroscopy). MATERIALS AND METHODS: There were 21 patients with FM and 27 HC who underwent conventional structural MR imaging and additional 2D-chemical shift imaging (CSI) MR-spectroscopy sequences. For the 2D-CSI spectroscopy, larger volumes of interest (VOIs) were centered at the level of the basal ganglia and the supraventricular white matter. Within these larger areas, 16 smaller voxels were placed in a number of regions previously implicated in pain processing. N-acetylaspartate (NAA)/creatine(Cr), choline (Cho)/Cr and NAA/Cho ratios were calculated for each voxel. Subjects underwent clinical and experimental pain assessment. RESULTS: Mean metabolite ratios and ratio variability for each region were analyzed by using repeated-measures analysis of variance (ANOVA). Correlations between clinical symptoms and metabolite ratios were assessed. Cho/Cr variability in the right dorsolateral prefrontal cortex (DLPFC) was significantly different in the 2 groups; a significant correlation between Cho/Cr in this location and clinical pain was present in the FM group. Evoked pain threshold correlated significantly with NAA/Cho ratios in the left insula and left basal ganglia. CONCLUSION: Our data suggest that there are baseline differences in the variability of brain metabolite relative concentrations between patients with FM and HC, especially in the right DLPFC. Furthermore, there are significant correlations between metabolite ratios and clinical and experimental pain parameters in patients with FM.
BACKGROUND AND PURPOSE: Widespread pain sensitivity in patients with fibromyalgia (FM) suggests a central nervous system (CNS)-processing problem. Therefore, it is conceivable that metabolic alterations exist in pain-processing brain regions of people with FM compared with healthy controls (HC) and that such metabolic data could correlate with clinical symptoms. The purpose of this study was to test these hypotheses using proton MR spectroscopy ((1)H-MR spectroscopy). MATERIALS AND METHODS: There were 21 patients with FM and 27 HC who underwent conventional structural MR imaging and additional 2D-chemical shift imaging (CSI) MR-spectroscopy sequences. For the 2D-CSI spectroscopy, larger volumes of interest (VOIs) were centered at the level of the basal ganglia and the supraventricular white matter. Within these larger areas, 16 smaller voxels were placed in a number of regions previously implicated in pain processing. N-acetylaspartate (NAA)/creatine(Cr), choline (Cho)/Cr and NAA/Cho ratios were calculated for each voxel. Subjects underwent clinical and experimental pain assessment. RESULTS: Mean metabolite ratios and ratio variability for each region were analyzed by using repeated-measures analysis of variance (ANOVA). Correlations between clinical symptoms and metabolite ratios were assessed. Cho/Cr variability in the right dorsolateral prefrontal cortex (DLPFC) was significantly different in the 2 groups; a significant correlation between Cho/Cr in this location and clinical pain was present in the FM group. Evoked pain threshold correlated significantly with NAA/Cho ratios in the left insula and left basal ganglia. CONCLUSION: Our data suggest that there are baseline differences in the variability of brain metabolite relative concentrations between patients with FM and HC, especially in the right DLPFC. Furthermore, there are significant correlations between metabolite ratios and clinical and experimental pain parameters in patients with FM.
Authors: P C Sundgren; J Jennings; J T Attwood; B Nan; S Gebarski; W J McCune; Y Pang; P Maly Journal: Neuroradiology Date: 2005-07-09 Impact factor: 2.804
Authors: W Möller-Hartmann; S Herminghaus; T Krings; G Marquardt; H Lanfermann; U Pilatus; F E Zanella Journal: Neuroradiology Date: 2002-02-21 Impact factor: 2.804
Authors: J M Mountz; L A Bradley; J G Modell; R W Alexander; M Triana-Alexander; L A Aaron; K E Stewart; G S Alarcón; J D Mountz Journal: Arthritis Rheum Date: 1995-07
Authors: Dane B Cook; Gudrun Lange; Donald S Ciccone; Wen-Ching Liu; Jason Steffener; Benjamin H Natelson Journal: J Rheumatol Date: 2004-02 Impact factor: 4.666
Authors: Thorsten Giesecke; Richard H Gracely; Masilo A B Grant; Alf Nachemson; Frank Petzke; David A Williams; Daniel J Clauw Journal: Arthritis Rheum Date: 2004-02
Authors: A Gutzeit; D Meier; M L Meier; C von Weymarn; D A Ettlin; N Graf; J M Froehlich; C A Binkert; M Brügger Journal: Eur Radiol Date: 2010-10-02 Impact factor: 5.315
Authors: P Feraco; A Bacci; Fab Pedrabissi; L Passamonti; G Zampogna; Fed Pedrabissi; N Malavolta; M Leonardi Journal: AJNR Am J Neuroradiol Date: 2011-07-28 Impact factor: 3.825
Authors: B R Foerster; M Petrou; R E Harris; P B Barker; E G Hoeffner; D J Clauw; P C Sundgren Journal: AJNR Am J Neuroradiol Date: 2011-08-25 Impact factor: 3.825
Authors: Marieke E van Der Schaaf; Iris C Schmits; Megan Roerink; Dirk E M Geurts; Ivan Toni; Karin Roelofs; Floris P De Lange; Urs M Nater; Jos W M van der Meer; Hans Knoop Journal: BMC Psychiatry Date: 2015-07-03 Impact factor: 3.630
Authors: Nicolas Fayed; Javier Garcia-Campayo; Rosa Magallón; Helena Andrés-Bergareche; Juan V Luciano; Eva Andres; Julián Beltrán Journal: Arthritis Res Ther Date: 2010-07-07 Impact factor: 5.156
Authors: Andreas Gutzeit; Dieter Meier; Johannes M Froehlich; Klaus Hergan; Sebastian Kos; Constantin V Weymarn; Kai Lutz; Dominik Ettlin; Christoph A Binkert; Jochen Mutschler; Sabine Sartoretti-Schefer; Mike Brügger Journal: Eur Radiol Date: 2012-09-12 Impact factor: 5.315